LYMPHATICA MEDTECH CLOSES € 17.9 M SERIES B FUNDING ROUND TO DRIVE INNOVATION IN LYMPHEDEMA TREATMENT Lymphatica Medtech SA, EPFL Innovation Park Building E, 1015 Lausanne, Switzerland

Lausanne, October 8th, 2024 – Lymphatica Medtech SA, a clinical-stage company based in Lausanne,
Switzerland, specialized in innovative treatments for lymphedema, has raised €17.9 million in Series B
funding. This investment will accelerate the clinical development and validation of LymphoDrain, a
breakthrough implantable device designed to treat lymphedema, a chronic vascular condition that
currently has no cure and affects millions worldwide. First of its kind, LymphoDrain is easy to implant
subcutaneously through a minimally invasive technique and it’s intended to provide unprecedent benefits
to patients by locally and actively replacing the lymphatic vessels draining function.


The funding round was co-led by Panakès Partners, TechWald Next S.p.A., and CDP Venture
Capital’s Digital Transition Fund, with participation from OCCIDENT, Zürcher Kantonalbank, and Club
Degli Investitori. Existing investors, including High-Tech Gründerfonds (HTGF), also participated in this
round.


To support its growth, Lymphatica has also opened a subsidiary in Italy to expand its R&D efforts and
manage manufacturing and clinical operations.


Lymphatica is further strengthened by the appointment of Dan Rose as the new Chairman of the Board;
Rose brings extensive leadership experience from LimFlow (acquired by Inari Medical), Direct Flow
Medical, Sequana Medical, and Medtronic. Additionally, Alessio Beverina, Managing Partner at
Panakès, and Lukas Guenther, Chief Investment Officer at TechWald Next, have joined the Board of
Directors, alongside existing independent board member Nanci Govinder.


“We are thrilled to have closed our Series B financing, which will enable us to advance the clinical
development of our groundbreaking technology for lymphedema patients,” said Dr. Marco Pisano, CEO
and co-founder of Lymphatica Medtech. “With the support of our investors and new board members, we
are one step closer to delivering a transformative solution that will significantly improve the lives of those
suffering from lymphedema.”


Valentina Triacca, COO and co-founder of Lymphatica Medtech, added: “Millions of people live with
chronic lymphedema, and current treatment options fall short of providing effective relief. This investment
allows us to continue advancing our LymphoDrain device, which has already shown promising results in
a pilot feasibility study.”


“Lymphatica has made impressive progress in developing a compelling technology that has the potential
to transform care and improve the lives of the many patients suffering from Lymphedema today” said Dan
Rose. “It is a privilege to join the Board as Chairman and to support the efforts of this great team”.


Alessio Beverina, Managing Partner at Panakès, stated: “Lymphatica is addressing a massive unmet
medical need, with over 10 million people affected by lymphedema. This technology has the potential to
transform the lives of those patients.”


Lukas Guenther, CIO of TechWald, emphasized how "with its technology, Lymphatica is well-positioned
to bring true sustainable clinical innovation in the treatment of lymphedema, greatly benefiting patients,
physicians, and healthcare systems in various countries around the world."


About Lymphatica Medtech


Lymphatica Medtech is a Swiss medical device company founded in July 2017. It is a spin-off of the Swiss
Federal Institute of Technology, Lausanne (EPFL) and of the Lausanne University Hospital (CHUV). The
Company vision is to become the leader in the development and marketing of innovative medical devices
for the treatment of lymphatic diseases. The company has developed LymphoDrain, a breakthrough
implantable device designed to treat lymphedema. LymphoDrain is easy to implant subcutaneously
through a minimally invasive technique and it’s intended to provide unprecedent benefits to millions of
lymphedema patients worldwide, by locally and actively replacing the lymphatic vessels draining function.


https://lymphaticamedtech.com/


Panakès Partners


Panakès Partners is a Venture Capital firm, based in Milan, which invests in the most ambitious
companies and teams, developing revolutionary technologies and products, in the field of life sciences,
aiming to improve the lives of people around the world. Panakès, founded in 2015 by Fabrizio Landi,
Alessio Beverina and Diana Saraceni, has 250 million under management.


https://www.panakes.it/


TechWald Holding S.p.A


TechWald Next S.p.A. is an Operational Holding Company supporting high growth potential early-stage
companies committed to develop Healthcare Innovation. TechWald has a key strategic focus on the
MedTech industry and medical devices, equipment, digital devices which can provide benefit and value
for Patients, Doctors, and Healthcare Systems.


https://www.techwald.com/


Digital Transition Fund (PNRR) - CDP Venture Capital SGR S.p.A.


CDP Venture Capital is an asset management company fostering innovation and economic development
in Italy. CDP Venture Capital supports innovative companies at all stages of their growth through both
direct and indirect investments. The Digital Transition Fund (PNRR) invests in small and medium-sized
enterprises that implement innovative solutions, particularly in the areas of artificial intelligence, cloud
computing, healthcare, Industry 4.0, cybersecurity, fintech, blockchain, microelectronics, and other fields
related to digital transition.


https://www.cdpventurecapital.it/cdp-venture-capital/it/home.page


OCCIDENT


OCCIDENT invests in deep tech start-ups with a focus on spin-offs originating from scientific research,
thus enabling concrete solutions for different challenges facing society today. As an owner-managed
venture capital investor with offices in Munich and Zug, OCCIDENT supports start-ups in the life sciences
and industrial tech sectors from the seed stage onwards and enables founding teams to achieve
outstanding results. With a strong entrepreneurial mindset, OCCIDENT invests its own money and
accompanies their portfolio companies over the long term.


https://www.occident.group/


About Zürcher Kantonalbank (ZKB)


Zürcher Kantonalbank is a leading universal bank in the Greater Zurich Area, with national roots and
international reach. As one of the largest and most active investors in Switzerland, Zürcher Kantonalbank
finances innovative start-ups with venture capital across various sectors, providing financial backing and
strategic guidance.


https://www.zkb.ch/en/home.html


About Club Degli Investitori


The Club degli Investitori is an association composed of over 400 entrepreneurs, executives, and
professionals who support startups and scale-ups founded by Italian entrepreneurs worldwide. An
investment through the Club is much more than just capital: it involves the engagement of a group of
international business angels whose network of contacts and experience is far more valuable than the
financial resources alone. The Club has invested over €60 million in more than 70 companies, which have
collectively raised over €2 billion and created over 6,500 jobs.


https://www.clubdeglinvestitori.it/it/


About High-Tech Gründerfonds (HTGF)


HTGF is one of the leading and most active early-stage investors in Germany and Europe, financing start-
ups in the fields of Deep Tech, Industrial Tech, Climate Tech, Digital Tech, Life Sciences and Chemistry.
Across its funds, HTGF has over 2 billion euros under management. Since its inception in 2005, HTGF
has financed more than 750 start-ups and achieved over 180 successful exits.


https://www.htgf.de/de/